{
  "ticker": "VERA",
  "company_name": "VERA",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04716231",
      "title": "Atacicept in Subjects With IgA Nephropathy",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "IgA Nephropathy, Berger Disease",
      "start_date": "2023-06-29",
      "completion_date": "2028-07",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07270445",
      "title": "Effect of Virtual Reality Use on Preoperative Anxiety",
      "status": "NOT_YET_RECRUITING",
      "phase": "NA",
      "condition": "Anxiety",
      "start_date": "2026-01-06",
      "completion_date": "2027-03-01",
      "enrollment": 0,
      "sponsor": "Vera Guttenthaler"
    },
    {
      "nct_id": "NCT07020923",
      "title": "Monthly Dosing of Atacicept in IgAN",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy (IgAN), Berger Disease",
      "start_date": "2025-05-29",
      "completion_date": "2027-09",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04348409",
      "title": "Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "COVID-19",
      "start_date": "2020-05-25",
      "completion_date": "2020-12-31",
      "enrollment": 0,
      "sponsor": "Azidus Brasil"
    },
    {
      "nct_id": "NCT06674577",
      "title": "A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease",
      "start_date": "2024-12-01",
      "completion_date": "2028-05-31",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06983028",
      "title": "Atacicept in Multiple Glomerular Diseases",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "pMN, IgAN, Nephrotic Syndrome, MCD, FSGS",
      "start_date": "2025-07-07",
      "completion_date": "2027-11",
      "enrollment": 0,
      "sponsor": "Vera Therapeutics, Inc."
    },
    {
      "nct_id": "NCT01761786",
      "title": "Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Myocardial Infarction, STEMI",
      "start_date": "2011-06",
      "completion_date": "2019-04-04",
      "enrollment": 0,
      "sponsor": "Vera HM Deneer"
    },
    {
      "nct_id": "NCT02101385",
      "title": "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Malignant Neoplasm of Breast, Breast Cancer",
      "start_date": "2014-04-03",
      "completion_date": "2022-09-09",
      "enrollment": 0,
      "sponsor": "Bryan Schneider, MD"
    },
    {
      "nct_id": "NCT05451225",
      "title": "Survey of Correction Officers Before and After a Targeted Education Campaign",
      "status": "COMPLETED",
      "phase": "NA",
      "condition": "Work-Related Condition",
      "start_date": "2020-01-08",
      "completion_date": "2022-03-05",
      "enrollment": 0,
      "sponsor": "Columbia University"
    },
    {
      "nct_id": "NCT03166527",
      "title": "Panzyga in CIDP Administered at Different Infusion Rates",
      "status": "UNKNOWN",
      "phase": "PHASE3",
      "condition": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "start_date": "2017-06-01",
      "completion_date": "2018-12-15",
      "enrollment": 0,
      "sponsor": "Vera Bril"
    }
  ],
  "summary": {
    "total_trials": 24,
    "by_phase": {
      "PHASE3": 3,
      "NA": 9,
      "PHASE2": 8,
      "PHASE4": 2,
      "": 2
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 1,
      "NOT_YET_RECRUITING": 1,
      "RECRUITING": 4,
      "COMPLETED": 12,
      "ENROLLING_BY_INVITATION": 1,
      "UNKNOWN": 2,
      "WITHDRAWN": 2,
      "TERMINATED": 1
    },
    "active_trials": 6,
    "completed_trials": 12,
    "conditions": [
      "Anxiety",
      "BK Virus Infection",
      "Breast Cancer, Triple Negative Breast Cancer",
      "Breast Neoplasm Malignant Female",
      "COVID-19",
      "COVID-19 Pneumonia",
      "Child Malnutrition",
      "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "Covid19",
      "Critical Illness",
      "First-Episode Psychosis",
      "IgA Nephropathy (IgAN), Berger Disease",
      "IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease",
      "IgA Nephropathy, Berger Disease",
      "Lupus Nephritis (LN)",
      "Malignant Neoplasm of Breast, Breast Cancer",
      "Multidetector Computed Tomography, Pulmonary Embolism and Thrombosis, Hypertension Pulmonary Secondary",
      "Myelodysplastic Syndromes",
      "Myocardial Infarction, STEMI",
      "Prone Position, Donors, Lung Procurement, Tissue Donors, Lung Transplantation",
      "Venous Thromboembolism (VTE), Intensive Care Medicine, Venous Thromboembolism",
      "Work-Related Condition",
      "pMN, IgAN, Nephrotic Syndrome, MCD, FSGS"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T10:02:45.549451",
    "search_query": "VERA",
    "url": "https://clinicaltrials.gov/search?term=VERA"
  }
}